Publication | Closed Access

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

Clinical TrialsCipaglucosidase AlfaPharmacotherapyMedicineLate-onset Pompe Disease